Ocular Therapeutix, Inc. (OCUL)
10.90
+0.33
(+3.12%)
USD |
NASDAQ |
Sep 02, 16:00
10.92
+0.02
(+0.18%)
After-Hours: 20:00
Ocular Therapeutix Research and Development Expense (Annual) : 197.10M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 197.10M |
| December 31, 2024 | 127.64M |
| December 31, 2023 | 61.06M |
| December 31, 2022 | 53.46M |
| December 31, 2021 | 50.08M |
| December 31, 2020 | 28.69M |
| December 31, 2019 | 41.09M |
| Date | Value |
|---|---|
| December 31, 2018 | 36.92M |
| December 31, 2017 | 30.19M |
| December 31, 2016 | 27.06M |
| December 31, 2015 | 26.61M |
| December 31, 2014 | 18.33M |
| December 31, 2013 | 10.11M |
| December 31, 2012 | 11.14M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| EyePoint, Inc. | 221.04M |
| LENZ Therapeutics, Inc. | 18.67M |
| Merck & Co., Inc. | 12.51B |
| Theravance Biopharma, Inc. | 35.91M |
| ANI Pharmaceuticals, Inc. | 51.66M |